Bioventus price target lowered to $15 from $17 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Bioventus (BVS) to $15 from $17 and keeps a Buy rating on the shares following quarterly results. The company noted that tariff exposure thus far remains minimal at less than $1M and is included in guidance. Though the firm says there may be additional risk from pharma tariffs on HA products, which have thus been excluded from the first round of tariffs.